Cardiovascular Systems (NASDAQ:CSII) issued its earnings results on Tuesday. The medical device company reported ($0.09) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.06) by ($0.03), MarketWatch Earnings reports. Cardiovascular Systems had a net margin of 0.79% and a return on equity of 1.36%. The company had revenue of $56.27 million during the quarter, compared to analysts’ expectations of $55.96 million. Cardiovascular Systems updated its FY 2019 guidance to EPS.
Shares of CSII traded down $6.31 during mid-day trading on Wednesday, reaching $28.61. The company had a trading volume of 32,918 shares, compared to its average volume of 229,355. The firm has a market cap of $1.18 billion, a PE ratio of 565.60 and a beta of 2.49. Cardiovascular Systems has a fifty-two week low of $20.58 and a fifty-two week high of $40.00. The company has a quick ratio of 4.03, a current ratio of 4.47 and a debt-to-equity ratio of 0.16.
A number of research analysts have issued reports on the stock. Lake Street Capital reaffirmed a “buy” rating and issued a $50.00 target price on shares of Cardiovascular Systems in a report on Wednesday, August 1st. BidaskClub lowered shares of Cardiovascular Systems from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, July 25th. Needham & Company LLC restated a “hold” rating on shares of Cardiovascular Systems in a research report on Wednesday. Stifel Nicolaus began coverage on shares of Cardiovascular Systems in a research report on Wednesday, August 22nd. They set a “buy” rating and a $45.00 target price on the stock. Finally, Zacks Investment Research lowered shares of Cardiovascular Systems from a “buy” rating to a “hold” rating in a research report on Friday, August 3rd. One equities research analyst has rated the stock with a sell rating, four have given a hold rating and five have given a buy rating to the company. The company has a consensus rating of “Hold” and an average price target of $35.20.
Cardiovascular Systems Company Profile
Cardiovascular Systems, Inc, a medical device company, develops, manufactures, and commercializes various devices to treat vascular and coronary diseases in the United States. The company offers peripheral arterial disease products, including Diamondback 360 Peripheral, Predator 360, Stealth 360 Peripheral Orbital Atherectomy System (OAS), Diamondback 360 60cm Peripheral OAS, Diamondback 360 Low Profile Peripheral, Diamondback 360 1.50 Peripheral, Diamondback 360 2.00 Peripheral, Diamondback 360 200cm Peripheral, and Diamondback 360 180cm Peripheral, which are catheter-based platforms for treating a range of plaque types in leg arteries above and below the knee, including calcified plaque, as well as address various limitations associated with surgical, catheter, and pharmacological treatment alternatives.
Featured Story: Understanding Compound Annual Growth Rate (CAGR)
Receive News & Ratings for Cardiovascular Systems Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cardiovascular Systems and related companies with MarketBeat.com's FREE daily email newsletter.